Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi Of Japan Working To Become Multinational

This article was originally published in PharmAsia News

Executive Summary

Japan's Shionogi has ambitious plans to transform itself into a multinational company in the pharmaceutical industry. It has five drugs in middle- to late-stage clinical trials in its three areas of concentration - infectious diseases and metabolic and pain syndromes. A new Shionogi administration took over the company April 1 and set goals for itself through its 2009 fiscal year. In the past the company has relied on ties to other multinationals for most of its earnings, but patents on most of those drugs are due to expire within the next 10 years. Already in the current fiscal year, Shionogi has seen its U.S. sales out-number sales in its home country. (Click here for more - a subscription may be required

You may also be interested in...



P&G Tapping Into UK Vegan Trend Via Nature’s Best

Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement. 

UK Shares How Its Medtech Regs Already Diverge From The EU: COVID-19 Marks The Start

The MHRA has updated its guidance on regulatory flexibilities for medical devices and medicinal products resulting from COVID-19 to highlight how its approach differs from the EU.

Carag Applies Bioabsorbable Material Technology To Transseptal Occluders

The Swiss company is planning a US trial of CBSO, the first transcatheter septal occluder with a bioresorbable, metal-free frame.

UsernamePublicRestriction

Register

LL1127945

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel